1.
DEGUELIN’S EFFECT ON
PANCREATIC CANCER
STEM CELLS
Semra Ece Akat & Doga Dag
Ozel Ege Lisesi, Turkey
#SciChallenge2017

2.
CONTENTS

3.
PANCREATIC CANCER
℘ Pancreas cancer is a type of cancer that distrupts the digestive system and keeps the
patiens away from eating food normally. It’s treatment is difficult and survival is
minimal, therefore, it is considered as one of the most dangerous cancer types.

4.
AIM OF THE PROJECT
℘ Tumors consist of cancerous stem cells, which is the smallest part of the tumor. No
medication can directly effect these stem cells. In this study, our aim is to obstruct the
spread of these stem cells and possibly eradicate them via apoptosis with the help of
Deguelin.
℘ According to the results of test subjects being exposed to Deguelin in different doses,
the recovery process of pancreas patients can be sped up with different calculations.

5.
DEGUELIN
℘ It’s a natural compound made from the plant Mundulea sericea (C23H22O6). Its also used
in insecticides. According to some studies, the compound enhances Deguelin’s anti-
tumor activity.

6.
PROCESS
℘ WST-I’s exhilaration percenteges were evaluated. With the result, the LD50 dose was
specified. According to literature, the amount of doses were found as 0,1 - 0,5 - 2 - 10 -
25 µM and MA: 394,42 g/mol. With this, the doses for 5-FU and Deguelin were defined
as 10 - 50 - 100 µM and 0,1 - 0,5 - 2 - 10 - 25 µM.
℘ The study was repeated at doses of 25-50-100-50 µM, when determined intervals
increased the viability. Then, isolation of CD133+ Mia root cells, confirmation of
CD133+ positivity by Flow Cytometry, and Annexin – PI dyeing procedures were
performed respectively.

7.
APOPTOSIS RESULTS
Group Viability Early
Apoptosis
Late
Apoptosis
Necrosis Total
Death
Mia
Control
%
71,0
% 26,9 % 1,8 - %
28,7
GroupGroup ViabilityViability EarlyEarly
ApoptosisApoptosis
LateLate
ApoptosisApoptosis
NecrosisNecrosis TotalTotal
DeathDeath
Mia Total
100 µM
Deguelin
% 16,4 % 4,9 % 78 % 35,3 % 83,6
GroupGroup ViabilityViability EarlyEarly
ApoptosisApoptosis
LateLate
ApoptosisApoptosis
NecrosisNecrosis TotalTotal
DeathDeath
Mia Total
200 µM 5-
FU
% 49,8 % 5,0 % 42,6 % 10,4 % 50,2
GroupGroup ViabilityViability EarlyEarly
ApoptosisApoptosis
LateLate
ApoptosisApoptosis
NecrosisNecrosis TotalTotal
DeathDeath
Mia Total
100 µM
Deguelin +
200 µM 5-
% 11,6 % 69,5 % 16,4 - % 88,4

8.
APOPTOSIS RESULTS
Group Viability Early
Apoptosis
Late
Apoptosis
Necrosis Total
Death
Mia Total
CD133+
Control
% 86,7 % 11,2 % 0,3 - % 11,5
Group Viability Early
Apoptosis
Late
Apoptosis
Necrosis Total
Death
Mia CD133+
100 µM
Deguelin
% 38,9 % 27,2 % 33,3 - % 61,1
Group Viability Early
Apoptosis
Late
Apoptosis
Necrosis Total
Death
Mia CD133+
200 µM 5-FU
% 34,1 % 31,2 % 33,9 - % 65,9

9.
APOPTOSIS RESULTS
Group Viability Early
Apoptosis
Late
Apoptosis
Necrosis Total
Death
Mia CD133+
100 µM
Deguelin +
200 µM 5-FU
% 24,2 % 31,2 % 39,5 - % 75,8

10.
RESULT
℘ Deguelin generates a vitro cytotxic effect in pancreatic cancer cells without the
distortion of the 5-FU influence and CD133+ roots for apoptosis. Deguelin has
proved successful in the treatment of pancreatic cancer when dosed alone at 100
µM, 5-FU 200 µM and dosed at 100 µM Deguelin + 200 µM 5-FU combined.
℘ In LD-50, better results were acquired when the two substance’s doses were
combined than when they were used separately. % 49.2 viability was found and
100 µM was used in the making of the LD-50 dose for Deguelin, 200 µM and
% 47.1 viability for 5-FU and ; % 45.5 viability in the combined dose.

11.
EVALUATION
℘ We recommend combination of 200 μM 5-FU and 100 μM Deguelin because this dose
has got more lethal effect than others.
GroupGroup ActivityActivity EarlyEarly
ApoptosisApoptosis
LateLate
ApoptosisApoptosis
NecrosisNecrosis TotalTotal
DeathDeath
Mia Total
100 µM
Deguelin +
200 µM 5-FU
% 11,6 % 69,5 % 16,4 - % 88,4

12.
APPLICABILITY
℘ With the use of Deguelin in pharmaceutical industry, we think that this will help
pancreas patients slow down their cancerous stem cells if used as the amount specified.